Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials
about
sameAs
Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?Aspirin for primary prevention of coronary heart diseaseVariation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke.Multimorbidity in chronic disease: impact on health care resources and costsSuppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancerCoronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implicationsAspirin under fire: aspirin use in the primary prevention of coronary heart diseaseAspirin for everyone older than 50? AgainstRole of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug usersWomen's health study (aspirin) and TNTAspirin resistanceReview of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agentsUse of statins and aspirin to reduce risks of cardiovascular diseaseInteraction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure?The public health potential of aspirinAspirin for the prevention of cardiovascular disease: calculating benefit and harm in the individual patientIs there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen?Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?Cardioprotective medication use in hemodialysis patientsCardioprotective aspirin users and their excess risk of upper gastrointestinal complicationsPrevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategiesDose of aspirin in the treatment and prevention of cardiovascular disease: current and future directionsMy health: whose responsibility? Low-dose aspirin and older peopleO2-acetoxymethyl-protected diazeniumdiolate-based NSAIDs (NONO-NSAIDs): synthesis, nitric oxide release, and biological evaluation studiesCirculating salicylic acid is related to fruit and vegetable consumption in healthy subjectsAnalysis of aspirin-associated risks in healthy individualsRole of clopidogrel in unstable angina and non-ST-segment elevation myocardial infarction: from literature and guidelines to practiceThe impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitorUse of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in SpainDocetaxel induced cardiotoxicityAcute pressure overload cardiac arrhythmias are dependent on the presence of myocardial tissue catecholaminesEffects of pretreatment with verapamil on early recurrences after electrical cardioversion of persistent atrial fibrillation: a randomised study.Aspirin delimits platelet life span by proteasomal inhibitionRelationship between Disgust and Memory Biases in Spider Fear.Non-invasive characterisation of coronary lesion morphology by multi-slice computed tomography: a promising new technology for risk stratification of patients with coronary artery diseaseManagement of cardiovascular complications in systemic lupus erythematosus.Thromboxane and the thromboxane receptor in cardiovascular disease.Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status.The relationship between infection, inflammation, and cardiovascular disease: an overview.Does low-dose ASA help prevent cardiovascular events in women?
P2860
Q22241777-69275B4F-5934-4C6C-95FC-4483C0F68BD9Q24247631-FBF626BB-09E9-4B8F-A281-953E31F9FD36Q24645957-A05C9EB4-F42A-42DD-ADFA-E638EEA3AE3FQ26741437-3E8FBF9A-AED1-4CBF-8AD5-724907AF8088Q28165770-2D895106-A3A8-43B1-8162-85BC7D499DCEQ28167649-FD1A8C23-0C99-4D1C-9073-E1469341CA1BQ28176243-9A7E6CC9-07C1-4667-BD2E-48167DB39825Q28180850-5E43B778-5E1F-4406-A29A-1389CF7B0C01Q28182449-53C1B852-7565-4BD2-9492-35D2BFC0A91CQ28184667-DB12D1AD-4C32-4A71-A82D-9994F77AFB09Q28187611-8C40FEEC-9937-415A-A2E7-C1C567A6C724Q28192470-122BE96C-9B61-4048-AF4C-FF098D56321EQ28193248-07DE9F1F-6CF4-4C04-9BE8-3E1909CFFD59Q28193462-EF9EC31F-4BBF-4CC1-97E9-3D4FC1A07203Q28194137-6FCC081D-C8CF-4136-924D-DB348C1FC367Q28195348-AC4ED02B-B43B-448D-A179-E522876B7F20Q28196511-5F160F8E-E53A-45D6-8EE7-1AC54A83F896Q28198746-E417678A-4FFF-44EC-8DEA-3DC3C61CFC45Q28199374-4843C645-5E97-43DF-B480-0F5A188CF312Q28200511-E6E39EBD-5CA8-40C7-A07C-198091DF1B2EQ28200569-65FC081E-609A-4AEB-B210-A5CEF6DEEC6FQ28200895-F5953DFD-ECF3-441D-8080-171E5CED0105Q28201631-DFA4E417-908D-4F84-A647-5D57967FA345Q28210989-870790F4-A933-4095-833E-88CA8D41B28FQ28211560-DD7B78FE-C17D-43E5-8221-0B2E11565675Q28211608-9CE43D26-D41C-4B6B-A89A-C242CEE8A55CQ28211998-9DE9A264-B992-4500-9E79-B27023EDF2C2Q28217400-8AA7BC98-4898-4A75-A1C0-26A04811D096Q28222880-63F01C27-0972-4C54-B622-BC2CFB773BB4Q28343995-75420C08-F366-443C-9D51-508182EF9F55Q28362668-CE40D933-6062-471F-AE32-1B027C7CDFBBQ28362672-D5D643D6-A012-4693-8EEC-ABAFFFA7A137Q28542013-38DFE802-46E1-4BC6-AF30-25B88DCEF14EQ30423378-1600A5BE-98DD-4620-89A5-A1D21EB45452Q30542175-970C2BBA-8911-428B-9451-490ACD3126E6Q33730536-9B12EC42-BBEC-4E26-BEC1-AB69230572E7Q33899567-30001EEC-BDEE-4BC7-B6E0-3970F2C83D7DQ34433987-9AAA93A0-EADC-4A53-A15D-899D15E8E531Q34557639-EA2D10A6-AC65-4C7A-BF93-22EB8544CF0AQ34683759-424BC919-4C24-4E52-83C8-C058E0DD9E19
P2860
Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Aspirin for primary prevention ...... -analysis of randomised trials
@ast
Aspirin for primary prevention ...... -analysis of randomised trials
@en
Aspirin for primary prevention ...... -analysis of randomised trials
@nl
type
label
Aspirin for primary prevention ...... -analysis of randomised trials
@ast
Aspirin for primary prevention ...... -analysis of randomised trials
@en
Aspirin for primary prevention ...... -analysis of randomised trials
@nl
prefLabel
Aspirin for primary prevention ...... -analysis of randomised trials
@ast
Aspirin for primary prevention ...... -analysis of randomised trials
@en
Aspirin for primary prevention ...... -analysis of randomised trials
@nl
P2093
P2860
P3181
P356
P1433
P1476
Aspirin for primary prevention ...... -analysis of randomised trials
@en
P2093
E J Wallis
L E Ramsay
P Ghahramani
P R Jackson
P S Sanmuganathan
P2860
P304
P3181
P356
10.1136/HEART.85.3.265
P407
P577
2001-03-01T00:00:00Z